INFU vs. TMCI, DCTH, NPCE, CLPT, TCMD, SMLR, NNOX, STIM, SMTI, and ZIMV
Should you be buying InfuSystem stock or one of its competitors? The main competitors of InfuSystem include Treace Medical Concepts (TMCI), Delcath Systems (DCTH), NeuroPace (NPCE), ClearPoint Neuro (CLPT), Tactile Systems Technology (TCMD), Semler Scientific (SMLR), Nano-X Imaging (NNOX), Neuronetics (STIM), Sanara MedTech (SMTI), and ZimVie (ZIMV). These companies are all part of the "medical equipment" industry.
InfuSystem vs.
Treace Medical Concepts (NASDAQ:TMCI) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Treace Medical Concepts received 17 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 44.83% of users gave Treace Medical Concepts an outperform vote.
84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 27.7% of Treace Medical Concepts shares are held by company insiders. Comparatively, 10.2% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
InfuSystem has a net margin of 1.12% compared to Treace Medical Concepts' net margin of -30.33%. InfuSystem's return on equity of 2.78% beat Treace Medical Concepts' return on equity.
Treace Medical Concepts presently has a consensus price target of $9.93, suggesting a potential upside of 40.23%. InfuSystem has a consensus price target of $13.00, suggesting a potential upside of 175.42%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts clearly believe InfuSystem is more favorable than Treace Medical Concepts.
InfuSystem has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
Treace Medical Concepts has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500.
In the previous week, Treace Medical Concepts had 28 more articles in the media than InfuSystem. MarketBeat recorded 28 mentions for Treace Medical Concepts and 0 mentions for InfuSystem. Treace Medical Concepts' average media sentiment score of 0.18 beat InfuSystem's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the media.
Summary
InfuSystem beats Treace Medical Concepts on 11 of the 19 factors compared between the two stocks.
Get InfuSystem News Delivered to You Automatically
Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InfuSystem Competitors List
Related Companies and Tools
This page (NYSE:INFU) was last updated on 4/30/2025 by MarketBeat.com Staff
